Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Martin Dreyling, MD, Eva Hoster, PhD, Michael Unterhalt, PhD, Andreas Rosenwald, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Wolfram Klapper

Blood (2019) 134 (Supplement_1): 3996.

https://doi.org/10.1182/blood-2019-130068

Published: 2019

Journal Articles

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Liat Vidal, MD MSc, Anat Gafter-Gvili, MD, Martin H. Dreyling, Michael Unterhalt, PhD, Pia Raanani, MD, Michele Ghielmini, MD professor, Ronit Gurion

Blood (2016) 128 (22): 1802.

https://doi.org/10.1182/blood.V128.22.1802.1802

Published: 2016

Journal Articles

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, PhD, Britta Kehden, Michael Unterhalt, PhD, Michael Herold, Richard H van der Jagt, Ann Janssens, MD, Michael Kneba, Jiri Mayer, MD, Chris Pocock, PhD FRCPath FRCP, Nathalie Danesi, PhD, Günter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Robert E Marcus, Wolfgang Hiddemann

Blood (2016) 128 (22): 613.

https://doi.org/10.1182/blood.V128.22.613.613

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group ( GLSG )

Vindi Jurinovic, M.Sc., Bernd Metzner, MD, PhD, Michael Pfreundschuh, MD, PhD, Norbert Schmitz, MD, PhD, Hannes Wandt, MD, PhD, Christian Peschel, MD, PhD, Martin Dreyling, MD PhD, Wolfgang Hiddemann, MD, PhD, Eva Hoster, PhD, Michael Unterhalt, PhD, Oliver Weigert, MD

Blood (2016) 128 (22): 3464.

https://doi.org/10.1182/blood.V128.22.3464.3464

Published: 2016

Journal Articles

A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy

Blood (2015) 126 (23): 333.

https://doi.org/10.1182/blood.V126.23.333.333

Published: 2015

Journal Articles

FLIPI and F2 Index – Prognostic Indices in Advanced Stage Follicular Lymphoma

Michael Unterhalt, PhD, Eva Hoster, Martin Dreyling, Christian Buske, Wolfgang Hiddemann, MD, on behalf of the German Low-Grade Lymphoma Study Group (GLSG)

Blood (2008) 112 (11): 2832.

https://doi.org/10.1182/blood.V112.11.2832.2832

Published: 2008

Journal Articles

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Eva Hoster, Michael Unterhalt, PhD, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Sonja Martin, Else Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling

Blood (2008) 112 (11): 3049.

https://doi.org/10.1182/blood.V112.11.3049.3049

Published: 2008

Journal Articles

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

Wolfgang Hiddemann, Christian Buske, Michael Kneba, MD, PhD, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Michael Unterhalt, PhD

Blood (2008) 112 (11): 772.

https://doi.org/10.1182/blood.V112.11.772.772

Published: 2008

Journal Articles

MRD Detection in Mantle Cell Lymphoma: Flow Cytometry Is Comparable to Consensus Primer IgH-PCR at Initial Staging, but Less Sensitive Than PCR after Combined Immuno-Chemotherapy.

Sebastian Boettcher, MD, Matthias Ritgen, MD, Reiner Siebert, MD, Sebastian Buske, Martina Klingenberg, Michael Unterhalt, PhD, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD, Michael Kneba, MD, PhD, Christiane Pott

Blood (2005) 106 (11): 1925.

https://doi.org/10.1182/blood.V106.11.1925.1925

Published: 2005

Journal Articles

Evidence for Fcγ Receptor IIIA-Independent Rituximab Effector Mechanisms in Patients with Follicular Lymphoma Treated with Combined Immuno-Chemotherapy.

Sebastian Boettcher, MD, Christiane Pott, MD, Matthias Ritgen, MD, Wolfgang Hiddemann, MD, Michael Unterhalt, PhD, Michael Kneba, MD, PhD

Blood (2004) 104 (11): 590.

https://doi.org/10.1182/blood.V104.11.590.590

Published: 2004

NARROW

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group ( GLSG )

A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy

FLIPI and F2 Index – Prognostic Indices in Advanced Stage Follicular Lymphoma

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

MRD Detection in Mantle Cell Lymphoma: Flow Cytometry Is Comparable to Consensus Primer IgH-PCR at Initial Staging, but Less Sensitive Than PCR after Combined Immuno-Chemotherapy.

Evidence for Fcγ Receptor IIIA-Independent Rituximab Effector Mechanisms in Patients with Follicular Lymphoma Treated with Combined Immuno-Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only